SG10202112024PA - Chimeric proteins and methods of immunotherapy - Google Patents
Chimeric proteins and methods of immunotherapyInfo
- Publication number
- SG10202112024PA SG10202112024PA SG10202112024PA SG10202112024PA SG10202112024PA SG 10202112024P A SG10202112024P A SG 10202112024PA SG 10202112024P A SG10202112024P A SG 10202112024PA SG 10202112024P A SG10202112024P A SG 10202112024PA SG 10202112024P A SG10202112024P A SG 10202112024PA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- methods
- chimeric proteins
- chimeric
- proteins
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277322P | 2016-01-11 | 2016-01-11 | |
US201662351522P | 2016-06-17 | 2016-06-17 | |
US201662399939P | 2016-09-26 | 2016-09-26 | |
US201662399902P | 2016-09-26 | 2016-09-26 | |
US201662399923P | 2016-09-26 | 2016-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202112024PA true SG10202112024PA (en) | 2021-12-30 |
Family
ID=59311397
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202112024PA SG10202112024PA (en) | 2016-01-11 | 2017-01-10 | Chimeric proteins and methods of immunotherapy |
SG11201805785TA SG11201805785TA (en) | 2016-01-11 | 2017-01-10 | Chimeric proteins and methods of immunotherapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805785TA SG11201805785TA (en) | 2016-01-11 | 2017-01-10 | Chimeric proteins and methods of immunotherapy |
Country Status (16)
Country | Link |
---|---|
US (3) | US10336807B2 (en) |
EP (2) | EP3901258A1 (en) |
JP (1) | JP7012645B2 (en) |
KR (1) | KR20180095719A (en) |
CN (1) | CN108463229B (en) |
AU (1) | AU2017207281B2 (en) |
BR (1) | BR112018013663A2 (en) |
CA (1) | CA3010754A1 (en) |
EA (1) | EA201891614A1 (en) |
ES (1) | ES2875747T3 (en) |
IL (1) | IL260528B2 (en) |
MX (1) | MX2018008345A (en) |
MY (1) | MY194127A (en) |
PH (1) | PH12018501453A1 (en) |
SG (2) | SG10202112024PA (en) |
WO (1) | WO2017123556A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018013679A2 (en) | 2016-01-11 | 2019-01-22 | Univ Leland Stanford Junior | chimeric proteins and gene expression regulation methods |
AU2017207281B2 (en) | 2016-01-11 | 2022-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of immunotherapy |
JP2019527192A (en) | 2016-05-31 | 2019-09-26 | カーディオバックス リミテッド ライアビリティ カンパニー | Diagnosis and treatment method for systemic lupus erythematosus |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
WO2018148649A1 (en) * | 2017-02-10 | 2018-08-16 | The Institute For Cancer Research D/B/A | Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance |
CN110753555A (en) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | Immune cells expressing engineered antigen receptors |
JP2020537498A (en) * | 2017-09-11 | 2020-12-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Antibody-mediated delivery of CAS9 to mammalian cells |
CA3085210A1 (en) * | 2017-12-14 | 2019-06-20 | Bluebird Bio, Inc. | Nkg2d daric receptors |
US11952413B2 (en) | 2017-12-14 | 2024-04-09 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes comprising interleukin receptor signaling domains |
WO2019152781A1 (en) * | 2018-02-02 | 2019-08-08 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates |
CA3093827A1 (en) * | 2018-03-14 | 2019-09-19 | Celledit Llc | Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy |
BR112020022010A2 (en) * | 2018-05-03 | 2021-01-26 | Board Of Regents, The University Of Texas System | natural killer cells modified to express chimeric antigen receptors with immune checkpoint block |
AU2019326617A1 (en) * | 2018-08-24 | 2021-03-18 | Locanabio, Inc. | FASL immunomodulatory gene therapy compositions and methods for use |
TW202034958A (en) * | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
US11279698B2 (en) * | 2018-11-20 | 2022-03-22 | Cornell University | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer |
SG11202105192WA (en) * | 2018-12-03 | 2021-06-29 | Fusion Pharmaceuticals Inc | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
US20220064277A1 (en) * | 2018-12-27 | 2022-03-03 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies for treating atherosclerosis |
EP3927830A4 (en) * | 2019-02-22 | 2022-11-30 | Refuge Biotechnologies, Inc. | Chimeric polypeptides and methods of using the same |
CN111676195A (en) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | UCAR immune cell for treating T cell tumor |
EP3938500A1 (en) * | 2019-03-12 | 2022-01-19 | University of Washington | Precise gene activation via novel designed proteins mediating epigenetic remodeling |
KR102323342B1 (en) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | Bispecific Antibody Against IL-17A and TNF-α |
JOP20210298A1 (en) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | Methods and compositions for preventing type 1 diabetes |
CN110115759B (en) * | 2019-05-29 | 2022-02-18 | 中国海洋大学 | Method for improving antiviral immunity of fish |
CN110201158B (en) * | 2019-06-11 | 2020-06-09 | 南京融捷康生物科技有限公司 | Pharmaceutical composition |
CN110330567B (en) * | 2019-07-02 | 2020-11-06 | 南京凯地生物科技有限公司 | Bispecific chimeric antigen receptor T cells, methods of making and uses thereof |
WO2021006604A1 (en) * | 2019-07-08 | 2021-01-14 | 주식회사 프로젠 | Novel fusion protein and use of same |
CN110327458B (en) * | 2019-07-09 | 2022-02-25 | 上海交通大学医学院 | Application of autocrine VEGFB in T cell metabolism and function and tumor immunotherapy |
CN112480237B (en) * | 2019-09-12 | 2023-10-17 | 上海津曼特生物科技有限公司 | Fusion protein and preparation method and application thereof |
WO2021061859A1 (en) | 2019-09-24 | 2021-04-01 | The Regents Of The University Of California | Novel receptors for ligand-dependent transcriptional regulation |
CN110964750A (en) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技(上海)有限公司 | Chimeric antigen receptor cell library carrying gene element combination, preparation and screening methods and application |
TW202140556A (en) * | 2020-01-17 | 2021-11-01 | 英屬開曼群島商百濟神州有限公司 | Anti-nkp30 antibodies and methods of use |
CN114945586A (en) * | 2020-01-21 | 2022-08-26 | 张晋宇 | Pharmaceutical composition and application thereof |
WO2021231436A1 (en) * | 2020-05-11 | 2021-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic methods for treating covid-19 infections |
CN115867294A (en) | 2020-06-04 | 2023-03-28 | 凯瑞斯马治疗公司 | Novel constructs for chimeric antigen receptors |
AU2021376208A1 (en) * | 2020-11-04 | 2023-06-22 | Senti Biosciences, Inc. | Protein payload release |
JP2023548560A (en) * | 2020-11-08 | 2023-11-17 | フンダサオ ディー. アンナ デ ソメール シャンパリモー エ ドトール カルロス モンテズ シャンパリモー ファウンデーション | Systems and methods for regulating gene expression or activity |
CN114539415B (en) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | anti-PD-L1/VEGF/TGF-beta multi-specific antibody and application thereof |
US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
WO2022170093A2 (en) * | 2021-02-05 | 2022-08-11 | University Of Utah Research Foundation | Compositions and methods for treating with car cells |
CA3213044A1 (en) * | 2021-03-23 | 2022-09-29 | Kole T. ROYBAL | Synthetic intermembrane proteolysis receptors for custom antigen-induced transcriptional regulation |
CN113186268B (en) * | 2021-05-08 | 2023-05-12 | 苏州海苗生物科技有限公司 | DNA-RNA hybrid double-strand specific conjugate and application thereof in promoting nucleic acid replication and detecting novel coronaviruses |
US20230032871A1 (en) * | 2021-07-14 | 2023-02-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Recombinant Viral Particle for Gene and/or Cellular Therapy |
CN113817621B (en) * | 2021-09-07 | 2023-02-17 | 天津大学 | Recombinant saccharomyces cerevisiae strain capable of simultaneously expressing IFNa14 protein and human hepatitis B virus S protein as well as preparation method and application thereof |
CN114621929B (en) * | 2021-12-21 | 2023-05-30 | 河南省肿瘤医院 | Antitumor dendritic cell, preparation method thereof, expression vector and application |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US812436A (en) | 1905-06-17 | 1906-02-13 | Douglas P Morrison | System of calibrating recording watt-hour meters. |
DE4129849A1 (en) * | 1991-02-14 | 1992-08-27 | Boehringer Mannheim Gmbh | MONOCLONAL ANTIBODIES AGAINST HUMANE PANCREAS ISLAND CELLS |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
DE69942334D1 (en) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS |
DK1107789T3 (en) | 1998-08-24 | 2008-11-03 | Univ Leland Stanford Junior | Compositions and methods for protecting organs, tissues and cells from damage mediated by the immune system |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
EP2269654A3 (en) | 1999-08-24 | 2011-04-13 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US7256286B2 (en) | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
ATE437647T1 (en) | 2001-02-16 | 2009-08-15 | Cellgate Inc | TRANSPORTER WITH SPACED ARGININE PARTICLES |
DE10211063A1 (en) | 2002-03-13 | 2003-10-09 | Axaron Bioscience Ag | New methods for the detection and analysis of protein interactions in vivo |
CA2479858A1 (en) | 2002-03-21 | 2003-10-02 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
WO2004067753A2 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US20070224615A1 (en) | 2003-07-09 | 2007-09-27 | Invitrogen Corporation | Methods for assaying protein-protein interactions |
CA2531698A1 (en) | 2003-07-09 | 2005-01-27 | Sentigen Biosciences, Inc. | Method for assaying protein-protein interaction |
FR2858235B1 (en) * | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS |
ATE466933T1 (en) | 2005-03-15 | 2010-05-15 | Cellectis | I-CREI MEGANUCLEASE VARIANTS WITH MODIFIED SPECIFICITY AND METHOD FOR THEIR PRODUCTION AND USE |
WO2007032793A1 (en) | 2005-05-27 | 2007-03-22 | Sentigen Bioscience, Inc. | Multiplex array useful for assaying protein-protein interaction |
US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
EP2325332B1 (en) | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
ES2384440T3 (en) | 2005-10-18 | 2012-07-04 | Precision Biosciences | Rationally designed meganucleases with sequence specificity and altered DNA binding affinity |
SG170058A1 (en) * | 2006-03-03 | 2011-04-29 | Elan Pharm Inc | Methods of treating inflammatory and autoimmune diseases with natalizumab |
ATE528647T1 (en) | 2006-03-16 | 2011-10-15 | Life Technologies Corp | METHOD FOR STUDYING PROTEIN-PROTEIN INTERACTIONS |
ES2590925T3 (en) | 2006-05-19 | 2016-11-24 | Dupont Nutrition Biosciences Aps | Marked microorganisms and marking methods |
WO2007149807A1 (en) | 2006-06-20 | 2007-12-27 | Invitrogen Corporation | Methods for identifying modifiers of gpr1 activity |
EP2205729A2 (en) | 2007-09-27 | 2010-07-14 | Sangamo BioSciences, Inc. | Genomic editing in zebrafish using zinc finger nucleases |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
US8645115B2 (en) | 2008-12-22 | 2014-02-04 | Trustees Of Boston University | Modular nucleic acid-based circuits for counters, binary operations, memory and logic |
CN106834320B (en) | 2009-12-10 | 2021-05-25 | 明尼苏达大学董事会 | TAL effector-mediated DNA modification |
WO2012166906A1 (en) | 2011-05-31 | 2012-12-06 | Massachusetts Institute Of Technology | Cell-directed synthesis of multifunctional nanopatterns and nanomaterials |
WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
US9732392B2 (en) | 2011-08-05 | 2017-08-15 | Northwestern University | Modular sensor architecture for cell based biosensors |
WO2013049330A1 (en) | 2011-09-28 | 2013-04-04 | The Regents Of The University Of California | Synthetic transcriptional control elements and methods of generating and using such elements |
AU2012354062B2 (en) | 2011-12-16 | 2017-09-07 | Targetgene Biotechnologies Ltd | Compositions and methods for modifying a predetermined target nucleic acid sequence |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
WO2014018423A2 (en) * | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
CN110066775B (en) | 2012-10-23 | 2024-03-19 | 基因工具股份有限公司 | Composition for cleaving target DNA and use thereof |
US20150315576A1 (en) | 2012-11-01 | 2015-11-05 | Massachusetts Institute Of Technology | Genetic device for the controlled destruction of dna |
CA3034794A1 (en) | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
JP2016505256A (en) | 2012-12-12 | 2016-02-25 | ザ・ブロード・インスティテュート・インコーポレイテッ | CRISPR-Cas component system, method and composition for sequence manipulation |
BR112015013784A2 (en) | 2012-12-12 | 2017-07-11 | Massachusetts Inst Technology | application, manipulation and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
PT2931898E (en) | 2012-12-12 | 2016-06-16 | Harvard College | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
ES2598115T3 (en) | 2012-12-12 | 2017-01-25 | The Broad Institute, Inc. | Systems engineering, methods and guide compositions optimized for sequence manipulation |
JP6552965B2 (en) | 2012-12-12 | 2019-07-31 | ザ・ブロード・インスティテュート・インコーポレイテッド | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
SG10201912991WA (en) | 2012-12-17 | 2020-03-30 | Harvard College | Rna-guided human genome engineering |
KR20220100093A (en) * | 2013-02-06 | 2022-07-14 | 안트로제네시스 코포레이션 | Modified t lymphocytes having improved specificity |
CN105142677B (en) | 2013-02-15 | 2019-08-30 | 加利福尼亚大学董事会 | Chimeric antigen receptor and its application method |
NZ712727A (en) | 2013-03-14 | 2017-05-26 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
US20160138027A1 (en) | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
AU2014227653B2 (en) | 2013-03-15 | 2017-04-20 | The General Hospital Corporation | Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
US9745368B2 (en) * | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
UY35468A (en) | 2013-03-16 | 2014-10-31 | Novartis Ag | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER |
AU2014265331B2 (en) | 2013-05-15 | 2019-12-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
KR102307280B1 (en) | 2013-06-05 | 2021-10-01 | 듀크 유니버시티 | Rna-guided gene editing and gene regulation |
SG11201509866TA (en) | 2013-06-06 | 2015-12-30 | Agency Science Tech & Res | Protease-responsive peptide biosensors and methods for analyte detection |
JP6738729B2 (en) | 2013-06-17 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling postmitotic cell diseases and disorders |
SG10201710487VA (en) | 2013-06-17 | 2018-01-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components |
AU2014287397B2 (en) | 2013-07-10 | 2019-10-10 | President And Fellows Of Harvard College | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing |
US20150044772A1 (en) * | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
WO2015026885A1 (en) | 2013-08-22 | 2015-02-26 | Pioneer Hi-Bred International, Inc. | Genome modification using guide polynucleotide/cas endonuclease systems and methods of use |
AU2014321138A1 (en) | 2013-09-12 | 2016-04-28 | The University Of Queensland | Bimolecular protease-based biosensor |
WO2015048690A1 (en) * | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Optimized small guide rnas and methods of use |
WO2015048577A2 (en) | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
AU2014352638B2 (en) * | 2013-11-25 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
CA2934436A1 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
EP3811970A1 (en) * | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
EP3126498A4 (en) | 2014-03-20 | 2017-08-23 | Université Laval | Crispr-based methods and products for increasing frataxin levels and uses thereof |
WO2015148670A1 (en) | 2014-03-25 | 2015-10-01 | Editas Medicine Inc. | Crispr/cas-related methods and compositions for treating hiv infection and aids |
EP3981876A1 (en) | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
US11439712B2 (en) | 2014-04-08 | 2022-09-13 | North Carolina State University | Methods and compositions for RNA-directed repression of transcription using CRISPR-associated genes |
KR20170032406A (en) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | Engineered cells for adoptive cell therapy |
EP3708155A1 (en) | 2014-10-31 | 2020-09-16 | Massachusetts Institute Of Technology | Massively parallel combinatorial genetics for crispr |
US20170369878A1 (en) | 2015-01-12 | 2017-12-28 | Massachusetts Institute Of Technology | Microrna combinations for anti-cancer therapeutics |
CN108064283B (en) * | 2015-02-24 | 2024-01-09 | 加利福尼亚大学董事会 | Binding triggered transcription switches and methods of use thereof |
WO2016149274A1 (en) | 2015-03-17 | 2016-09-22 | Brown University | Methods for labeling and manipulating a cellular circuit |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
WO2017008018A1 (en) | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Genetically engineered sensors for in vivo detection of bleeding |
EP3344803B1 (en) | 2015-09-01 | 2021-08-04 | The Regents of The University of California | Modular polypeptide libraries and methods of making and using same |
WO2017044476A1 (en) | 2015-09-08 | 2017-03-16 | Massachusetts Institute Of Technology | Methods and compositions for recombinase-based genetic diversification |
US10480009B2 (en) | 2015-10-01 | 2019-11-19 | Massachusetts Institute Of Technology | Biological state machines |
AU2017207281B2 (en) | 2016-01-11 | 2022-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of immunotherapy |
BR112018013679A2 (en) | 2016-01-11 | 2019-01-22 | Univ Leland Stanford Junior | chimeric proteins and gene expression regulation methods |
-
2017
- 2017-01-10 AU AU2017207281A patent/AU2017207281B2/en active Active
- 2017-01-10 ES ES17738809T patent/ES2875747T3/en active Active
- 2017-01-10 KR KR1020187023203A patent/KR20180095719A/en active Search and Examination
- 2017-01-10 EP EP21159359.5A patent/EP3901258A1/en not_active Withdrawn
- 2017-01-10 SG SG10202112024PA patent/SG10202112024PA/en unknown
- 2017-01-10 JP JP2018536108A patent/JP7012645B2/en active Active
- 2017-01-10 SG SG11201805785TA patent/SG11201805785TA/en unknown
- 2017-01-10 CN CN201780006442.9A patent/CN108463229B/en active Active
- 2017-01-10 EA EA201891614A patent/EA201891614A1/en unknown
- 2017-01-10 EP EP17738809.7A patent/EP3402494B1/en active Active
- 2017-01-10 CA CA3010754A patent/CA3010754A1/en active Pending
- 2017-01-10 MX MX2018008345A patent/MX2018008345A/en unknown
- 2017-01-10 BR BR112018013663A patent/BR112018013663A2/en unknown
- 2017-01-10 MY MYPI2018702380A patent/MY194127A/en unknown
- 2017-01-10 WO PCT/US2017/012881 patent/WO2017123556A1/en active Application Filing
-
2018
- 2018-07-06 US US16/029,299 patent/US10336807B2/en active Active
- 2018-07-06 PH PH12018501453A patent/PH12018501453A1/en unknown
- 2018-07-10 IL IL260528A patent/IL260528B2/en unknown
-
2019
- 2019-05-16 US US16/414,721 patent/US11111287B2/en active Active
-
2022
- 2022-10-28 US US17/975,887 patent/US20230416336A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3010754A1 (en) | 2017-07-20 |
WO2017123556A1 (en) | 2017-07-20 |
SG11201805785TA (en) | 2018-08-30 |
US20180346543A1 (en) | 2018-12-06 |
EP3901258A1 (en) | 2021-10-27 |
MX2018008345A (en) | 2018-12-06 |
CN108463229B (en) | 2023-10-17 |
US10336807B2 (en) | 2019-07-02 |
EP3402494B1 (en) | 2021-04-07 |
PH12018501453A1 (en) | 2019-03-18 |
KR20180095719A (en) | 2018-08-27 |
US11111287B2 (en) | 2021-09-07 |
BR112018013663A2 (en) | 2019-01-22 |
IL260528A (en) | 2018-08-30 |
AU2017207281B2 (en) | 2022-03-10 |
EA201891614A1 (en) | 2019-02-28 |
EP3402494A1 (en) | 2018-11-21 |
IL260528B1 (en) | 2023-03-01 |
IL260528B2 (en) | 2023-07-01 |
US20190345220A1 (en) | 2019-11-14 |
JP7012645B2 (en) | 2022-01-28 |
ES2875747T3 (en) | 2021-11-11 |
AU2017207281A1 (en) | 2018-07-19 |
JP2019504835A (en) | 2019-02-21 |
MY194127A (en) | 2022-11-14 |
US20230416336A1 (en) | 2023-12-28 |
EP3402494A4 (en) | 2019-07-17 |
CN108463229A (en) | 2018-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202112024PA (en) | Chimeric proteins and methods of immunotherapy | |
ZA202004919B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
IL304117A (en) | Anti-pvrig antibodies and methods of use | |
IL265800A (en) | Anti-lag-3 antibodies and methods of use thereof | |
HK1258058A1 (en) | Anti-tigit antibodies and methods of use | |
HK1252858A1 (en) | Anti-cll-1 antibodies and methods of use | |
SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
HK1254743A1 (en) | Novel anti-claudin antibodies and methods of use | |
ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
EP3390442A4 (en) | Anti-c5 antibodies and methods of use | |
IL265957A (en) | Anti-c1s antibodies and methods of use thereof | |
HK1258850A1 (en) | Anti-tpbg antibodies and methods of use | |
SG10202007893TA (en) | Methods of immunotherapy |